Resumen de acción MRTX
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Mirati Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.70 |
| 52 Week High | US$64.41 |
| 52 Week Low | US$27.30 |
| Beta | 0.77 |
| 1 Month Change | -0.41% |
| 3 Month Change | 6.32% |
| 1 Year Change | 18.92% |
| 3 Year Change | -71.20% |
| 5 Year Change | -5.55% |
| Change since IPO | 590.59% |
Noticias y actualizaciones recientes
Recent updates
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Oct 05
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?
Jun 22Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
May 17We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully
Feb 01Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates
Dec 09We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
Oct 08Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?
Sep 11Mirati: A Potential Blockbuster Stock, Will Need Patience
Sep 08Mirati jumps 11% as Amgen meets key goal for rival cancer drug
Aug 31Mirati gains as Amgen posts new combination data for rival cancer drug
Aug 08Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues
Aug 08Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years
Jun 21Rentabilidad de los accionistas
| MRTX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -0.5% | -1.5% | -0.7% |
| 1Y | 18.9% | 0.1% | 22.3% |
Rentabilidad vs. Industria: MRTX superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.
Rentabilidad vs. Mercado: MRTX igualó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
| MRTX volatility | |
|---|---|
| MRTX Average Weekly Movement | 1.0% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: MRTX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MRTX ha disminuido de 10% a 1% en el último año.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1995 | 587 | Chuck Baum | www.mirati.com |
Resumen de fundamentos de Mirati Therapeutics, Inc.
| Estadísticas fundamentales de MRTX | |
|---|---|
| Capitalización bursátil | US$4.12b |
| Beneficios(TTM) | -US$725.88m |
| Ingresos (TTM) | US$38.19m |
107.8x
Ratio precio-ventas (PS)-5.7x
Ratio precio-beneficio (PE)¿Está MRTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MRTX | |
|---|---|
| Ingresos | US$38.19m |
| Coste de los ingresos | US$510.48m |
| Beneficio bruto | -US$472.29m |
| Otros gastos | US$253.59m |
| Beneficios | -US$725.88m |
Últimos beneficios comunicados
Sep 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -10.35 |
| Margen bruto | -1,236.66% |
| Margen de beneficio neto | -1,900.65% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado MRTX a largo plazo?
Ver rendimiento histórico y comparativa